Patient Square Capital LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001819257

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q1 2026 · 29 positions · Total reported value $563.61M · Top-10 concentration 73.3% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 69.0% · 6 new · 8 cut · 6 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q1 2026 13F filing, Patient Square Capital LP disclosed 29 equity positions with a combined reported value of $563.61M. The filing implies a focused portfolio: its ten largest positions account for 73.3% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2026 were ROIV ($226.20M), ARGX ($26.81M), INSM ($25.75M). By sector, the heaviest allocations are Health Care 98.2%, Industrials 1.8%. Versus the prior quarter, allocation shifted toward Health Care (+4.0pp) and away from Industrials (-1.2pp), Other (-2.8pp).

Versus the prior quarter, Patient Square Capital LP opened 6 new positions, trimmed 8 and fully exited 6, a turnover rate of 69.0% of positions. The portfolio's overlap with the prior quarter was 63% of names.

The largest new positions opened in Q1 2026 were BLTE ($18.60M), LEGN ($17.91M), NKTR ($15.11M).

Of the 6 positions fully exited versus the prior quarter, the largest were TERN ($12.93M), LQDA ($7.83M), OCUL ($5.95M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2026)

  • BLTE BELITE BIO INC · $18.60M
  • LEGN LEGEND BIOTECH CORP · $17.91M
  • NKTR NEKTAR THERAPEUTICS · $15.11M
  • MRK MERCK & CO · $9.62M
  • DFTX DEFINIUM THERAPEUTICS INC · $6.26M
  • TARA PROTARA THERAPEUTICS INC · $5.37M
  • CTMX CYTOMX THERAPEUTICS INC. · $5.10M

Fully Exited (vs previous quarter)

  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $12.93M
  • LQDA LIQUIDIA CORPORATION · prev qtr: $7.83M
  • OCUL OCULAR THERAPEUTIX INC · prev qtr: $5.95M
  • IRON DISC MEDICINE INC · prev qtr: $5.88M
  • AVTX AVALO THERAPEUTICS INC · prev qtr: $5.67M
  • AMLX AMYLYX PHARMACEUTICALS INC · prev qtr: $4.23M

Insider Transactions (Form 4)

Latest Patient Square Capital LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Patient Square Capital LP is a Menlo Park, CA-based investment firm founded by David Goel and Stephen Mandel Jr. with approximately $17.5 billion in assets under management.

Investment Approach

They employ a long-term, concentrated investment strategy focusing on high-quality companies with strong competitive advantages.

Asset Classes

Primarily invests in US equities, as evidenced by their SEC Form 13F filings.

Notable Facts

Founded in 2016, known for activist investment style, sometimes taking significant positions in companies and advocating for changes.

Key People

Founded by David Goel and Stephen Mandel Jr. (co-founder of Lone Pine Capital).

For official disclosures, refer to the firm's SEC filings.

Sector Allocation

Health Care 98.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 8.17M $226.20M 40.13%
40.13%
Hold
2 36.72K $26.81M 4.76%
4.76%
Add
3 157.50K $25.75M 4.57%
4.57%
Reduce
4 80.54K $23.92M 4.24%
4.24%
Add
5 596.00K $22.94M 4.07%
4.07%
Add
6 230.00K $21.25M 3.77%
3.77%
Reduce
7 116.68K $18.60M 3.30%
3.30%
New
8 990.00K $17.91M 3.18%
3.18%
New
9 210.00K $15.11M 2.68%
2.68%
New
10 693.53K $14.49M 2.57%
2.57%
Add
11 493.00K $13.93M 2.47%
2.47%
Reduce
12 121.25K $13.50M 2.40%
2.40%
Reduce
13 227.00K $13.20M 2.34%
2.34%
Add
14 95.00K $10.84M 1.92%
1.92%
Reduce
15 795.00K $10.25M 1.82%
1.82%
Add
16 80.00K $9.62M 1.71%
1.71%
New
17 400.64K $9.44M 1.68%
1.68%
Add
18 3.45M $8.42M 1.49%
1.49%
Reduce
19 100.00K $8.33M 1.48%
1.48%
Reduce
20 93.88K $7.88M 1.40%
1.40%
Reduce
21 200.00K $7.84M 1.39%
1.39%
Reduce
22 1.62M $6.78M 1.20%
1.20%
Add
23 331.00K $6.26M 1.11%
1.11%
New
24 165.21K $5.83M 1.03%
1.03%
Add
25 1.03M $5.37M 0.95%
0.95%
New
26 1.09M $5.10M 0.91%
0.91%
New
27 195.00K $4.21M 0.75%
0.75%
Add
28 136.31K $3.78M 0.67%
0.67%
Add
29 1.00K $50.44K 0.01%
0.01%
Reduce

FAQ

What did Patient Square Capital LP buy in 2026-Q1?

In its 2026-Q1 13F filing, Patient Square Capital LP reported 29 equity positions worth $563.61M in aggregate; its largest disclosed positions were ROIV ($226.20M), ARGX ($26.81M), INSM ($25.75M).

How large is Patient Square Capital LP's portfolio?

Patient Square Capital LP reported $563.61M of long equity holdings across 29 positions as of 2026-Q1. Top-10 holdings account for 73.3% of reported value.

What is Patient Square Capital LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/patient-square-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →